Impact of the COVID-19 pandemic on antiviral drug development for other community-acquired respiratory viruses’ infections

Elsevier

Available online 1 August 2022

TherapiesSummary

The coronavirus disease 2019 (COVID-19) pandemic indirectly resulted in missed therapeutic opportunities for many diseases. Here we focus on community-acquired respiratory viruses other than severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) [respiratory syncytial virus, parainfluenza and influenza A], and highlight the pandemics impact on clinical trials to develop novel therapies for other severe respiratory viral infections. We retrospectively reviewed inclusion rates within respiratory antiviral clinical trials in comparison with all other clinical trials in our clinical investigations center, before and during the COVID-19 pandemic. As opposed to the remaining clinical trials developed within our unit, respiratory antiviral trials inclusion rates did not recover after the initial recruitment decrease observed across all trials during the first pandemic wave. These results were discussed in the context of non-COVID-19 respiratory viral infection rates within our center, showing a general decline in seasonal respiratory viruses spread since the COVID-19 pandemic onset. Virus epidemiology changes upon the wide SARS-CoV-2 expansion as well as the lifestyle changes globally adopted to prevent SARS-CoV-2 transmission could have therefore contributed to the negative impact of the COVID-19 pandemic on antiviral drug development. Our study highlights the peculiarity of respiratory antiviral drug development during the COVID-19 pandemic era and describes potential explanations for such drug development halting.

AbbreviationsCIC

clinical investigation center

COVID-19

coronavirus disease 2019

HSCT

hematopoietic stem cell-transplanted patient

PCR

polymerase chain reaction

RSV

respiratory syncytial virus

SARS-CoV2

severe acute respiratory syndrome coronavirus 2

Keywords

COVID-19 pandemic

SARS-CoV-2

Respiratory virus infections

Antiviral drug development

Clinical trials

View Abstract

© 2022 Published by Elsevier Masson SAS on behalf of Société française de pharmacologie et de thérapeutique.

留言 (0)

沒有登入
gif